Champions Oncology annual operating margin
2018
2019
2020
2021
2022
2023
2024
2025
2026
Champions Oncology's operating margin was −1.92% for fiscal 2026.
View full Champions Oncology company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-04-30 | −1.92% | −9.91 pp |
| 2025 | 2025-04-30 | 8.00% | +22.66 pp |
| 2024 | 2024-04-30 | −14.67% | −4.91 pp |
| 2023 | 2023-04-30 | −9.76% | −10.99 pp |
| 2022 | 2022-04-30 | 1.24% | +0.34 pp |
| 2021 | 2021-04-30 | 0.89% | +6.87 pp |
| 2020 | 2020-04-30 | −5.98% | −6.98 pp |
| 2019 | 2019-04-30 | 1.00% | +7.69 pp |
| 2018 | 2018-04-30 | −6.69% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2026 | 2026-04-30 | −3.77% | +12.47 pp |
| Q3 2026 | 2026-01-31 | −1.67% | −28.07 pp |
| Q2 2026 | 2025-10-31 | 1.23% | −4.20 pp |
| Q1 2026 | 2025-07-31 | −3.77% | −13.22 pp |
| Q4 2025 | 2025-04-30 | −16.24% | −14.30 pp |
| Q3 2025 | 2025-01-31 | 26.40% | +47.85 pp |
| Q2 2025 | 2024-10-31 | 5.43% | +22.32 pp |
| Q1 2025 | 2024-07-31 | 9.45% | +29.77 pp |
| Q4 2024 | 2024-04-30 | −1.94% | +17.34 pp |
| Q3 2024 | 2024-01-31 | −21.44% | −2.20 pp |
| Q2 2024 | 2023-10-31 | −16.89% | −16.94 pp |
| Q1 2024 | 2023-07-31 | −20.32% | −18.25 pp |
| Q4 2023 | 2023-04-30 | −19.29% | −16.87 pp |
| Q3 2023 | 2023-01-31 | −19.24% | −25.53 pp |
| Q2 2023 | 2022-10-31 | 0.05% | −2.18 pp |
| Q1 2023 | 2022-07-31 | −2.07% | −0.51 pp |
| Q4 2022 | 2022-04-30 | −2.42% | +3.71 pp |
| Q3 2022 | 2022-01-31 | 6.29% | −2.79 pp |
| Q2 2022 | 2021-10-31 | 2.23% | +2.16 pp |
| Q1 2022 | 2021-07-31 | −1.56% | −1.81 pp |
| Q4 2021 | 2021-04-30 | −6.12% | +17.09 pp |
| Q3 2021 | 2021-01-31 | 9.08% | +4.28 pp |
| Q2 2021 | 2020-10-31 | 0.07% | −3.75 pp |
| Q1 2021 | 2020-07-31 | 0.25% | +9.37 pp |
| Q4 2020 | 2020-04-30 | −23.21% | −21.71 pp |
| Q3 2020 | 2020-01-31 | 4.80% | +10.56 pp |
| Q2 2020 | 2019-10-31 | 3.82% | −0.29 pp |
| Q1 2020 | 2019-07-31 | −9.11% | −16.84 pp |
| Q4 2019 | 2019-04-30 | −1.50% | +10.64 pp |
| Q3 2019 | 2019-01-31 | −5.75% | −4.44 pp |
| Q2 2019 | 2018-10-31 | 4.11% | +5.45 pp |
| Q1 2019 | 2018-07-31 | 7.73% | +20.03 pp |
| Q4 2018 | 2018-04-30 | −12.15% | — |
| Q3 2018 | 2018-01-31 | −1.32% | — |
| Q2 2018 | 2017-10-31 | −1.35% | — |
| Q1 2018 | 2017-07-31 | −12.30% | — |
Over the last five reported fiscal years, Champions Oncology's operating margin decreased from 0.89% to −1.92%, a change of −2.81 percentage points. The latest reported quarter, Q4 2026, shows −3.77%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Champions Oncology filings at SEC.gov ↗